SCHEMBL30169745

SCHEMBL30169745

[2H]C1Oc2ccccc2CC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
MAOA P21397 3/20 0.45
MAOB P27338 3/20 0.45
CYP2A6 P11509 1/20 0.42
OXTR P30559 1/20 0.38
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.34
ITGB2 P05107 1/20 0.34
ICAM1 P05362 1/20 0.34
ITGAL P20701 1/20 0.34
BCHE P06276 1/20 0.32
CES1 P23141 1/20 0.32
AHR P35869 1/20 0.31
PDK2 Q15119 1/20 0.31
LMNA P02545 2/20 0.31
CRHBP P24387 2/20 0.31
CRHR2 Q13324 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30450885 0.81 CYP1A2 (0.54) CYP1A2MAOAMAOBCYP2A6OXTR
SCHEMBL3962887 0.81 CYP1A2 (0.54) CYP1A2MAOAMAOBCYP2A6OXTR
SCHEMBL987924 0.76 CYP2A6 (0.52) CYP1A2MAOAMAOBCYP2A6OXTR
SCHEMBL10462577 0.74 MAOA (0.73) CYP1A2MAOAMAOBCYP2A6BCHE
SCHEMBL7466845 0.69 ABCG2 (0.65) CYP1A2MAOAMAOBOXTRPKM
SCHEMBL8012703 0.68 MAOA (0.50) CYP1A2MAOAMAOBCYP2A6OXTR
SCHEMBL7606738 0.68 MAOA (0.70) CYP1A2MAOAMAOBOXTRTSHR
SCHEMBL29366435 0.67 CYP1A2 (1.00) CYP1A2MAOAMAOBCYP2A6TSHR
SCHEMBL77106 0.67 CYP1A2 (1.00) CYP1A2MAOAMAOBCYP2A6TSHR
SCHEMBL489968 0.67 MAOA (0.61) CYP1A2MAOAMAOBOXTRTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2023-07-25 US disclosed
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2023-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease CCNE2, CCNE1, CCNT1 CYP1A2 43/4885MAOA 1482/4885MAOB 353/4885
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE CCNE2, CCNE1, CCNT1 CYP1A2 43/4885MAOA 1482/4885MAOB 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.